Goal Reached Thanks to every supporter — we hit 100%!

Goal: 1000 CNY · Raised: 1000 CNY

100.0%
Get alerts for future matching vulnerabilitiesLog in to subscribe
I. Basic Information for CVE-2018-18975
Vulnerability Information

Have questions about the vulnerability? See if Shenlong's analysis helps!
View Shenlong Deep Dive ↗

Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.

Vulnerability Title
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Description
An issue was discovered in the Ascensia Contour NEXT ONE app for iOS before 2019-01-15. An attacker may proxy communications between the app and Ascensia backend servers because of a weak certificate-pinning implementation, leading to disclosure of medical information.
Source: NVD (National Vulnerability Database)
CVSS Information
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Type
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Title
Ascensia Diabetes Care Ascensia Contour NEXT ONE application 信息泄露漏洞
Source: CNNVD (China National Vulnerability Database)
Vulnerability Description
Ascensia Diabetes Care Ascensia Contour NEXT ONE application是美国Ascensia Diabetes Care公司的一款血糖仪管理应用程序。 基于iOS平台的Ascensia Diabetes Care Ascensia Contour NEXT ONE应用程序2019-01-15之前版本中存在安全漏洞。攻击者可利用该漏洞泄露病例信息。
Source: CNNVD (China National Vulnerability Database)
CVSS Information
N/A
Source: CNNVD (China National Vulnerability Database)
Vulnerability Type
N/A
Source: CNNVD (China National Vulnerability Database)
Affected Products
VendorProductAffected VersionsCPESubscribe
-n/a n/a -
II. Public POCs for CVE-2018-18975
#POC DescriptionSource LinkShenlong Link
AI-Generated POCPremium

No public POC found.

Login to generate AI POC
III. Intelligence Information for CVE-2018-18975
Please Login to view more intelligence information
IV. Related Vulnerabilities
V. Comments for CVE-2018-18975

No comments yet


Leave a comment